

## Healthcare industry BW

# SYGNIS Pharma AG secures further financial resources with shareholder loan

**SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today executed a subordinated loan agreement for a total amount of EUR 6 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini), with an interest-rate at customary market conditions. As a result this loan, which is payable on demand, secures the financing of SYGNIS' existing operations, according to the present plans, at least until the end of 2012.**

The loan is unsecured, bears no expiry date and may be terminated not before 30 September 2012. In this case the loan is to be repaid within a one month period. The loan agreement will be dissolved through dievini's corresponding participation in a future capital increase with shareholders subscription rights. In addition, instead of requesting a repayment of the loan, dievini is entitled to a repayment by way of a contribution in kind as part of a capital increase with shareholders subscription rights.

Alternatively repayment can be made in return for shares by way of a convertible bond programme, which is yet to be agreed upon. Prerequisite for these repayment options are the resolution and execution of a capital increase with shareholders subscription rights or a convertible bond programme as well as the creation of the conditional capital necessary for the second option through decision of SYGNIS' Annual General Meeting and registration in the commercial register.

### Weitere Informationen

SYGNIS Pharma AG  
Im Neuenheimer Feld 515  
69120 Heidelberg

Phone: +49 6221/ 454 6  
Fax: +49 6221/ 454 700  
Email: [contact\(at\)sygnis.de](mailto:contact(at)sygnis.de)

---

### Press release

22-Jun-2011  
Source: Sygnis Pharma AG (15.06.2011) (P)



# SYGNIS